1. Home
  2. FATE vs AXR Comparison

FATE vs AXR Comparison

Compare FATE & AXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • AXR
  • Stock Information
  • Founded
  • FATE 2007
  • AXR 1961
  • Country
  • FATE United States
  • AXR United States
  • Employees
  • FATE N/A
  • AXR N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • AXR Homebuilding
  • Sector
  • FATE Health Care
  • AXR Real Estate
  • Exchange
  • FATE Nasdaq
  • AXR Nasdaq
  • Market Cap
  • FATE 116.5M
  • AXR 122.8M
  • IPO Year
  • FATE 2013
  • AXR N/A
  • Fundamental
  • Price
  • FATE $1.47
  • AXR $23.84
  • Analyst Decision
  • FATE Hold
  • AXR
  • Analyst Count
  • FATE 6
  • AXR 0
  • Target Price
  • FATE $3.30
  • AXR N/A
  • AVG Volume (30 Days)
  • FATE 3.1M
  • AXR 7.8K
  • Earning Date
  • FATE 11-11-2025
  • AXR 09-09-2025
  • Dividend Yield
  • FATE N/A
  • AXR N/A
  • EPS Growth
  • FATE N/A
  • AXR 40.98
  • EPS
  • FATE N/A
  • AXR 2.48
  • Revenue
  • FATE $8,470,000.00
  • AXR $48,454,000.00
  • Revenue This Year
  • FATE N/A
  • AXR $28.57
  • Revenue Next Year
  • FATE N/A
  • AXR N/A
  • P/E Ratio
  • FATE N/A
  • AXR $9.70
  • Revenue Growth
  • FATE N/A
  • AXR N/A
  • 52 Week Low
  • FATE $0.66
  • AXR $17.60
  • 52 Week High
  • FATE $3.50
  • AXR $39.68
  • Technical
  • Relative Strength Index (RSI)
  • FATE 62.81
  • AXR 48.81
  • Support Level
  • FATE $1.30
  • AXR $23.34
  • Resistance Level
  • FATE $1.65
  • AXR $25.89
  • Average True Range (ATR)
  • FATE 0.17
  • AXR 0.85
  • MACD
  • FATE 0.02
  • AXR -0.07
  • Stochastic Oscillator
  • FATE 73.77
  • AXR 28.90

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About AXR AMREP Corporation

Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.

Share on Social Networks: